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Abstract
Background: Higher left ventricular mass (LV) strongly predicts cardiovascular mortality in hemodialysis patients.
Although several parameters of preload and afterload have been associated with higher LV mass, whether these
parameters independently predict LV mass, remains unclear.
Methods: This study examined a cohort of 391 adults with incident hemodialysis enrolled in the Predictors of
Arrhythmic and Cardiovascular Risk in End Stage Renal Disease (PACE) study. The main exposures were systolic and
diastolic blood pressure (BP), pulse pressure, arterial stiffness by pulse wave velocity (PWV), volume status estimated
by pulmonary pressures using echocardiogram and intradialytic weight gain. The primary outcome was baseline left
ventricular mass index (LVMI).
Results: Each systolic, diastolic blood, and pulse pressure measurement was significantly associated with LVMI by
linear regression regardless of dialysis unit BP or non-dialysis day BP measurements. Adjusting for cardiovascular
confounders, every 10 mmHg increase in systolic or diastolic BP was significantly associated with higher LVMI (SBP
β = 7.26, 95 % CI: 4.30, 10.23; DBP β = 10.05, 95 % CI: 5.06, 15.04), and increased pulse pressure was also associated
with higher LVMI (β = 0.71, 95 % CI: 0.29, 1.13). Intradialytic weight gain was also associated with higher LVMI but
attenuated effects after adjustment (β = 3.25, 95 % CI: 0.67, 5.83). PWV and pulmonary pressures were not associated
with LVMI after multivariable adjustment (β = 0.19, 95 % CI: −1.14, 1.79; and β = 0.10, 95 % CI: −0.51, 0.70, respectively).
Simultaneously adjusting for all main exposures demonstrated that higher BP was independently associated with
higher LVMI (SBP β = 5.64, 95 % CI: 2.78, 8.49; DBP β = 7.29, 95 % CI: 2.26, 12.31, for every 10 mmHg increase in BP).
Conclusions: Among a younger and incident hemodialysis population, higher systolic, diastolic, or pulse pressure,
regardless of timing with dialysis, is most associated with higher LV mass. Future studies should consider the use
of various BP measures in examining the impact of BP on LVM and cardiovascular disease. Findings from such
studies could suggest that high BP should be more aggressively treated to promote LVH regression in incident
hemodialysis patients.
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Background
Left ventricular hypertrophy (LVH) is the most frequently
observed cardiac abnormality in end-stage renal disease
(ESRD), and strongly predicts cardiovascular mortality in
hemodialysis patients [1]. Despite past findings demonstrat-
ing associations between various cardiac parameters and
LVH [2–4], independent, modifiable, and clinically relevant
predictors of left ventricular mass (LVM) in ESRD patients
remain difficult to define. Clinical trials have shown that
treatment of anemia and baseline factors such as cardiac
troponin T, C-reactive protein, IL-6, and serum albumin
are not associated with LV progression over follow-up [5].
Furthermore, the relative importance of various modifiable
risk factors in predicting LVH in incident dialysis patients
(i.e. patients transitioning from chronic kidney disease
[CKD] to ESRD), in particular, remains unclear, as the ma-
jority of studies have included prevalent dialysis patients,
predominantly Europeans, with potential survivor and se-
lection bias as well as small sample sizes limiting analyses.
African-Americans have also not been as extensively stud-
ied despite the high risk of hypertension and LVH prior to
ESRD in this population.
Hypertension is a major risk factor for LVH, and the
role of blood pressure (BP) in the progression of LVM and
mortality of patients receiving hemodialysis has been well
documented [6]. The timing of BP measurements, how-
ever, has been controversial in dialysis patients, as BP
levels are highly variable and BP measurements at a single
time point may not be a reliable estimate of the arterial
pressure load [7, 8].
Other factors associated with LVH are arterial stiff-
ness and volume overload. Aortic pulse wave velocity
(PWV) predicts cardiovascular disease and mortality
in patients with hypertension and ESRD [9–11], and
increased arterial stiffness measured by PWV is also
associated with an increase in LVH or LVM in cross-
sectional analyses of prevalent dialysis patients [2, 12].
Volume overload is closely associated with hyperten-
sion due to the positive sodium balance, which leads
to hypertension and increased extracellular volume
[13]. Studies have suggested that controlling for circu-
latory volume can decrease BP, contribute to LVH re-
gression, and improve survival [13, 14].
These parameters of arterial compliance and ven-
tricular volume [2, 15], pre- and post-hemodialysis sys-
tolic blood pressure (SBP) [3, 4], and intradialytic
weight gain (IDWG) [13, 14] have been implicated with
higher left ventricular mass index (LVMI). However,
these associations have not been consistently associated
in studies likely due to the complicated interrelation-
ship among these factors. Furthermore, there are only a
few studies that incorporate all these vascular and vol-
ume measures and determine the independent associa-
tions of vascular, arterial, and volume measures with
LVM, as most studies with smaller sample sizes demon-
strate that a single factor is associated with LVMI.
However, clinically, it is important to understand which
factor should be of most importance. This study there-
fore examines the relevant importance and the inde-
pendent roles of blood pressure, arterial stiffness, and
volume in predicting LVH using modifiable risk factors
that are clinically relevant and available in a large pro-
spective cohort of incident hemodialysis participants.
Methods
Study participants
We conducted cross-sectional analyses using data from
participants enrolled in the Predictors of Arrhythmic and
Cardiovascular Risk in End Stage Renal Disease (PACE)
study, which enrolled 402 adult incident hemodialysis pa-
tients who completed a baseline cardiovascular study visit.
The methods of the PACE study have been described in
detail previously [16]. Briefly, PACE is a prospective co-
hort study in the greater Baltimore area, which enrolled
participants from November 2008 to August 2012 from
27 outpatient dialysis units. Eligible participants were
hemodialysis patients aged 18 years or older within six
months of hemodialysis initiation, and able to provide in-
formed consent. Participants were excluded if they were
on home dialysis, had active cancer other than nonmela-
noma skin cancer, had a pacemaker/automatic implant-
able cardiac defibrillator, had detectable atrial fibrillation
at the time of echocardiogram, were pregnant, were nurs-
ing mothers or were non-English speaking patients. In this
analysis, participants without LVMI measurements were
further excluded.
The study protocol was approved by the institutional
review board of the Johns Hopkins School of Medicine,
MedStar Health Systems, and by the medical director of
each dialysis unit. All participants provided informed
written consent.
Data collection
Data were collected by self-report from standardized
questionnaires and also during study visits at the Johns
Hopkins Institute for Clinical and Translational Re-
search (ICTR). All participants underwent a study visit
with detailed cardiovascular evaluations by trained tech-
nologists or study staff including echocardiogram, PWV
and BP assessments on non-dialysis days to ensure uni-
formity across the study population. Based on the stud-
ies of myocardial stunning during dialysis and at the end
of dialysis treatments with many shifts in fluids and elec-
trolytes, the study visit was set to a non-dialysis day in
order to standardize the study visits for all dialysis pa-
tients and asses their cardiac status at a steady state.
Data on all hemodialysis treatment parameters and avail-
able laboratory tests during outpatient dialysis therapy
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were also provided by Davita Clinical Research and
MedStar Health Systems.
The echocardiograms (Toshiba Artida, Japan) were
performed by three trained technologists at baseline, to
determine left ventricular (LV) stroke volume, LV ejec-
tion fraction, and LVMI with 4 chamber views and
standard calculations for LVM. The M-mode by the
parasternal short axis view was used to estimate LVM,
as the long axis view can result in the improper align-
ment and overestimate LV dimensions and mass [17].
All cardiovascular studies were centrally read. Very few
participants at baseline had heart failure indicated by
low ejection fraction (1 %). Additionally, we estimated
pulmonary artery pressures based on measured velocity
of the tricuspid regurgitant (TR) jet. Aortic PWV mea-
sures were performed supine on the non-fistula arm
after at least 5 min of rest using the right carotid and
right femoral arteries by four investigators, and the aug-
mentation index was measured using radial tonometry
using the Sphygmocor PVx System (AtCor Medical,
West Ryde, Australia) device [18]. PWV measurements
were performed in the morning under similar conditions
in all participants and appropriate quality control mea-
sures were performed. Additionally, patients were fasting
prior to the assessment [18].
The exposure variables of interest included measures
of volume (pulmonary artery pressures and IDWG), and
vascular and arterial measurements. Vascular measure-
ments included SBP and diastolic blood pressure (DBP),
mean arterial pressure (MAP), pulse pressure, PWV, and
augmentation index. Four different measurements of
SBP or DBP and pulse pressure at various time points
were included. Predialysis BP measures taken at the dia-
lysis units were examined as (1) a three-month average
of the predialysis measurements taken using automated
BP measurements prior to the study visit and (2) a single
measurement closest to the study visit. Non-dialysis BP
measures taken at the study vist on a non-dialysis day
were examined as: (1) an average of three standardized
BP measures conducted using the Omron HEM-907 BP
measuring device (Omron Healthcare, Kyoto, Japan) in a
seated and (2) an average of three BP measures collected
using the same method in a supine position. Volume
status was estimated by pulmonary artery pressure based
on TR from the echocardiogram [19–21], as the presence
of pulmonary hypertension occurs when TR jet velocity
exceeds 3.4 m/s [22]. Furthermore, echocardiographic pa-
rameters such as left atrial diameters, which may be re-
flective of the filling pressure and influenced by TR, have
been associated with excess volume in hemodialysis (HD)
patients [23]. Volume measurement also included IDWG,
and this was analyzed as: 1) a three-month average of
IDWG measurements taken at the dialysis units, and 2) a
measurement closest to the study visit.
The primary endpoint was LVMI calculated by Dever-
eux’s formula [24], as recommended by the American
Society of Echocardiography [17], using left ventricular
internal diameter (LVID), interventricular septal thick-
ness (IVST) and left ventricular posterior wall thickness
(PWT):
LVMI g=m2
  ¼ 0:8 1:04 IVSTþ LVIDþ PWTð Þ3‐LVID3  
þ0:6gÞ=BSA
LVH was defined as LVMI greater than 116 g/m2 in
males and LVMI greater than 104 g/m2 in females.
Additional variables included self-reported age at en-
rollment, sex, and ethnicity. Body-mass index (BMI) and
waist to hip ratio (WHR) were determined during the
ICTR visits. Comorbidities were identified by detailed
chart review of medical records and included history of
hypertension, hypercholesterolemia, smoking status, dia-
betes mellitus, coronary artery disease (CAD), congestive
heart failure (CHF) and peripheral vascular disease (PVD),
dialysis frequency, cause of ESRD, time since first nephrol-
ogy visit, antihypertensive medications, and the Charlson
Comorbidity Index (CCI). Medications were determined
at baseline by medical record review from dialysis elec-
tronic patient records and participant questionnaire dur-
ing the study visit. Medications were also brought in for
review by the study team. As a result, adherence to medi-
cation treatment was not specifically assessed. Antihyper-
tensive medications were grouped into the following
categories: (1) Renin-angiotensin-aldosterone system
(RAAS) blockade (angiotensin-converting-enzyme inhibi-
tor [ACEi] or angiotensin II receptor blocker [ARB]), (2)
β-blocker or α- and β-blocker, (3) α-blocker, vasodilator,
or calcium channel blocker, (4) centrally acting agent, and
(5) other. Dietary sodium intake was calculated from a
24-h diet recall at the baseline study visit. Dialysis unit
hemoglobin data were included as a 3 month average
prior to the study visit.
Statistical analysis
For categorical variables, frequencies and percentages
with 95 % confidence intervals (CI) were used; for con-
tinuous variables, means with standard deviations (± SD)
were used for normally distributed data and median with
interquartile range for skewed distributed data.
Multiple analyses were used to examine the association
of BP, arterial stiffness, and volume with LVMI. To assess
the associations of each vascular, arterial and volume
measurement with LVMI, a multivariable linear regression
for each vascular, arterial or volume measure was con-
ducted. To assess the independent association of each
main explanatory measure with LVMI, all vascular, arter-
ial, and volume measures were simultaneously adjusted
for in the final multivariable linear regression model. Each
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vascular measure was modeled in a separate multivariable
model due to the high correlation between the vascular
measurements. The multivariable models were con-
structed using the forward selection model building ap-
proach, and included age, sex, ethnicity, BMI, history of
hypercholesterolemia, smoking, diabetes mellitus, coron-
ary heart disease, congestive heart failure, cause of end-
stage renal disease, time since first nephrology visit, beta
blocker and RAAS blockade use, number of antihyperten-
sive medication, and dietary sodium intake. To ensure the
consistency and the validity of the final model, all omitted
variables were included back into the final model and this
indicated that there were no significant changes in the
main estimates. Correlation and variance inflation factor
tests indicated a low degree of multicollinearity among all
factors. Tests of non-linearity indicated that there were no
significant non-linear effects. Patients with missing antihy-
pertensive medication data (14 %) were grouped into a
separate category. All other missing values for covariates
were imputed using the multiple imputation by chained
equations method [25]. The imputed variables with miss-
ing values were WHR (4.1 %), history of hypercholesterol-
emia (4.3 %), CCI (2.6 %), dietary sodium intake (5.9 %),
and time since first nephrology visit (1.0 %).
Given the high proportion of African American pa-
tients in this study, we tested for an interaction between
the exposure variables and ethnicity (African Americans
vs. non-African Americans) in stratified models. We also
stratified the results from the multivariable regression
models using pre-identified groups of IDWG (0-2 kg,
2-3 kg, and >3 kg), by β-blocker medication status [26],
and by RAAS blockade use.
A two-tailed P value of < 0.05 was considered statisti-
cally significant. All analyses were performed using
Stata/SE 12.0 (StataCorp, College Station, TX).
Results
Of the 402 participants who completed the study visits
with an echocardiogram, 11 were excluded due to poor
echocardiographic windows for measurement of LVMI.
The final study cohort comprised of 391 patients. Table 1
summarizes the baseline participant, vascular, volume, and
echocardiogram measurement characteristics. The study
population has mean age at enrollment of 54.7 years, me-
dian BMI of 27.9 kg/m2 and are predominantly male and
African American. Cardiovascular risk factors are com-
mon: 57 % with diabetes, 33 % with CAD, 41 % with CHF,
20 % with PVD, and 62 % has a history of smoking. The
vast majority is on two to three antihypertensive medica-
tions with approximately 62 % taking a beta-blocker and
39 % on any RAAS blockade. A total of 306 patients
(78 %) have demonstrable LVH.
Figure 1 illustrates side-by-side scatterplots of LVMI,
SBP, and DBP by type of BP measurement. In all four
measurements of BP, SBP and DBP have graded linear
associations with LVMI; however, DBP consistently
shows a steeper slope with LVMI than SBP. These pat-
terns are consistent regardless of timing of the BP meas-
urement. Figure 2 illustrates the quartiles of non-dialysis
seated BP measurements and trends of LVMI, stratified
by ethnicity. The plots demonstrate a significant positive
association between quartiles of SBP and DBP, and
LVMI among African Americans. Among non-African
Americans, only SBP is significantly associated with
LVMI. Similar associations are depicted using other BP
measurements (Additional file 1: Figure S1–S3).
The associations of vascular and volume measures
with LVMI are examined and shown in Table 2. The un-
adjusted linear regression model demonstrates that,
among vascular measures, BP, pulse pressure, and MAP
are all associated with higher LVMI. In particular, all
SBPs and DBPs, regardless of the timing of the measure-
ments, are most significantly associated with LVMI.
Among volume measures, only IDWG just prior to the
study visit is significantly associated with higher LVMI.
Adjusting for baseline covariates demonstrates that BP
measures remains significantly associated with higher
LVMI and the association with IDWG is attenuated. In
particular, DBPs are the most important factors among
BPs. Measures of arterial stiffness or pulmonary pres-
sure, after multivariable adjustment, are not associated
with LVMI.
Table 3 demonstrates the independent associations of
non-dialysis seated BP, PWV, and volume measures with
LVMI using a multivariable linear regression model that
simultaneously adjusted for the main explanatory measures
and other covariates. Among all BP, arterial, and volume
measurements, SBP and DBP are independently associated
with LVMI. Similar associations are demonstrated using
other vascular measures (predialysis, pulse pressure, mean
arterial pressure; Additional file 1: Table S1–S4). PWV and
IDWG measures are not independently associated with
LVMI.
Given the high proportion of African American pa-
tients, we first examined the interaction between ethni-
city and the exposure variables, and then stratified the
results from the adjusted model (Additional file 1:
Table S5). The stratified analysis by ethnicity demon-
strates that in African Americans, most BPs, pulse pres-
sures, and MAP are significantly associated with LVMI,
whereas in non-African Americans, few factors were as-
sociated with LVMI (Additional file 1: Table S5). There
are no significant interactions between ethnicity and
the explanatory variables.
We also postulated that the associations of BPs and
LVMI might not be constant across participants with vary-
ing IDWG. In the stratified analyses (Additional file 1:
Table S6), among those in the lowest IDWG group
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Age (years) 391 54.7 (±13.2)
Male 391 229 (58.6 %)
Ethnicity
African American 391 284 (72.6 %)
Non-African American 107 (27.4 %)
Body mass index (kg/m2) 391 27.9 (23.8, 33.2)
Waist to hip ratio 375 0.95 (±0.08)
Ever smoker 391 242 (61.9 %)
Hypercholesterolemia 374 225 (57.5 %)
Hypertension 391 390 (99.7 %)
Diabetes mellitus 391 224 (57.3 %)
Coronary artery disease 391 130 (33.3 %)
Congestive heart failure 391 160 (40.9 %)
Peripheral vascular disease 387 77 (19.9 %)
Dietary sodium intake (mg) 368 2219.1 (1370.3,
3045.1)
Hemoglobin (predialysis 3 month
average)
361 10.5 (±1.2)
Charlson comorbidity index 381 5 (3, 6)
Medications
ACEi or ARB 336 154 (46.6 %)
β-blocker or α- and β-blocker 336 242 (61.9 %)
α-blocker or vasoilator or calcium
channel blocker
336 271 (69.3 %)
Centrally acting agent 336 47 (12.0 %)
Diuretic 336 80 (20.5 %)
Total number of antihypertensive
medications
1 medication 336 48 (12.3 %)
2 medications 109 (27.9 %)
3 medications 106 (27.1 %)
> 4 medications 73 (18.7 %)
Cause of end-stage renal disease
Diabetes 391 136 (34.8 %)
Hypertension 100 (25.6 %)
Glomerulonephritis 54 (13.8 %)
Other 62 (15.9 %)
Unknown 39 (10.0 %)
Time since first nephrology visit
0 months 387 83 (21.2 %)
< 3 months 53 (13.6 %)
3 months - 12 months 68 (17.4 %)
> 12 months 183 (46.8 %)
Table 1 Baseline characteristics of incident hemodialysis
participants (Continued)
Three times a week dialysis 386 386 (98.7 %)
Three to four hour dialysis session 389 344 (88.0 %)
Hemodialysis access
Arteriovenous fistula 389 120 (30.7 %)
Other 271 (69.3 %)
Polyflux dialysis membranea 391 300 (76.7 %)
Vascular Measurements
Blood pressure (mmHg)
Predialysis (3 month average)
Systolic 383 153.0 (±16.8)
Diastolic 84.0 (±11.3)
Predialysis (Prior to study visit)
Systolic 380 154.9 (±26.0)
Diastolic 84.2 (±15.8)
Non-dialysis (Seated)
Systolic 387 136.6 (±25.2)
Diastolic 74.5 (±14.9)
Non-dialysis (Supine)






Predialysis (3 months average) 383 69.0 (±13.1)
Predialysis (Prior to study visit) 380 69.7 (±20.1)
Non-dialysis (Seated) 387 62.1 (±17.9)
Non-dialysis (Supine) 367 68.8 (±18.3)
Arterial Stiffness Measurements
Pulse wave velocity (m/s) 337 11.2 (±3.9)





Intradialytic weight gain (3 month
average) (kg)
383 2.3 (±1.1)




Left ventricular ejection fraction 391 65.3 (±12.0)
Left ventricular mass (g) 391 286.5 (±98.7)
Left ventricular mass index (g/m2) 391 150.0 (±49.0)
Left ventricular hypertrophyb 391 306 (78.3 %)
ARB angiotensin II receptor blocker, ACEi
angiotensin-converting-enzyme inhibitor
aPolyflux, Gambro dialyzer with a polymer blend of polyarylethersulfone,
polyvinylpyrrolidone, and polyamide dialysis membrane
bLVMI ≥ 116 g/m2 in males, ≥ 104 g/m2 in females
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(<2 kg), most BP measurements and pulse pressures are
significantly associated with LVMI. In the intermediate
IDWG group (2–3 kg), most BP measures are significantly
associated with LVMI. In the highest IDWG group
(>3 kg), no measures are associated with LVMI; however,
the sample size is extremely small.
Based on recent trial findings that demonstrate a differ-
ence in cardiovascular morbidity between β-blocker- and
ACEi-based therapy [26], we also stratified by β-blocker
medication status (Additional file 1: Table S7) and RAAS
blockade use (Additional file 1: Table S8). Among patients
who received no β-blockers, some BP measures and
IDWG prior to study visit are significantly associated with
higher LVMI. Among patients who received β-blocker
medications, most vascular measures are associated with
higher LVMI. There are no significant differences in the
mean BPs between patients who received β-blockers and
did not receive β-blockers. In patients who received RAAS
blockade, most vascular measures are significantly associ-
ated with higher LVMI. In patients who did not receive
RAAS blockade, few measures are associated with higher
LVMI. There are also no differences in the mean BPs be-
tween patients who did and did not receive RAAS
blockade.
Discussion
Among an ethnically diverse cohort incident to
hemodialysis, measures of afterload are consistently and
independently associated with higher LVMI in a linear
graded response even after controlling for other cardiovas-
cular disease risk factors and antihypertensive medica-
tions. Arterial stiffness and pulmonary pressure are not
associated with LVMI. This suggests that, of all vascular,
arterial, and volume measures, afterload reduction as mea-
sured by BP is an important factor associated with higher
LVMI in those starting dialysis, and thus significant in
managing cardiovascular risk for those patients during the
early initiation of hemodialysis.
Our study extends findings from the longitudinal
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Fig. 1 Scatterplots of left ventricular mass index (LVMI) and systolic and diastolic blood pressure at various time points as a three-month average
of the predialysis measurement prior to the study visit; b predialysis measurement prior to the study visit; c seated non-dialysis BP measurement
and d supine non-dialysis measurement
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examines changes in LV structure and function in pa-
tients transitioning from CKD to ESRD but could not
examine the role of clinical factors associated with LV
disease [27]. We are able to demonstrate, in a similar
but larger population of incident HD patients, significant
associations of modifiable risk factors, in particular,
blood and pulse pressures, with LVM. Our findings are
also consistent in a subgroup of patients without a prior
history of CHF (Additional file 1: Table S9). We report
fewer patients with LVH and mostly with preserved car-
diac function, which may be reflective of a younger and
more ethnically diverse study population. Our findings
also confirm and extend findings from the Erythropoi-
etin Normalization trial that showed a significant associ-
ation between higher SBP and LVM [5], as we are able
to demonstrate consistently higher LVMI with either
SBPs or DBPs at various time points and controlling for
measures of volume status and arterial stiffness and not
just SBP. Furthermore, no significant associations be-
tween hemoglobin and LVMI were found in our analysis
(Additional file 1: Table S10). Recent reviews have sug-
gested using non-dialysis BPs for management, however,
it is complicated to obtain morning BPs unless patients
are capable of home monitoring [28, 29]. A 24-h ambu-
latory BP monitoring would provide the best BP mea-
surements [30], but this is costly and impractical for all
dialysis patients [31]. Although both systolic and dia-
stolic BPs are associated with higher LVMI in this study,
DBP consistently shows a stronger association with
LVMI in comparison to SBP. This finding deviates from
earlier studies where higher predialysis SBP is the main
arterial hemodynamic factor associated with LVH pro-
gression [32]. The stronger association of DBP with
LVMI in our study could be attributed to the predomin-
antly African American study population or due to a se-
verely affected diseased population. Comparison of SBP,
DBP and pulse pressure with mortality on dialysis pa-
tients demonstrated that DBP significantly attenuates
the association of SPB and pulse pressure on mortality
and thus is an important factor leading to mortality [33].
The association between higher DBP and higher LV
mass may be indicative of lower LV diastolic function in
our cohort, which is often a consequence of LVH. A
meta-analysis of trials has also demonstrated that the re-
duction of diastolic BP in particular is important in the
regression of LVH [34]. Nonetheless, the direction of ef-
fect is consistent for either systolic or diastolic pressures.
Despite the findings of previous studies, evidence to
guide BP management in dialysis patients still remains
sparse [30]. The guidelines from the Kidney Disease Out-
comes Quality Initiative and the Joint National Committee
suggest that the goal BP should be less than 140/90 mmHg
[35, 36], however, the Kidney Disease: Improving Global
Outcomes states that these recommendations are largely
based on expert opinion and weak evidence, and does not
provide a recommendation regarding BP management in
dialysis patients [30]. Our results show that approximately
79 % of those receiving dialysis with a predialysis BP
Fig. 2 Boxplot of left ventricular mass index (LVMI) and quartiles of systolic or diastolic blood pressures measured as a seated non-dialysis BP
measurement stratified by ethnicity a and b non-African Americans and c and d African American participants
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greater than 140/90 mmHg had higher LVMI. Further-
more, our study reflects the proportion of patients at dia-
lysis initiation as they transition from advanced CKD to
hemodialysis, and this provides a window to potentially
mitigate cardiovascular risk on dialysis by aggressively
treating high BP at early stages of dialysis. We are also
able to demonstrate, in our large incident cohort, that BP
is associated with higher LVMI regardless of timing. Clini-
cians could use predialysis measures for adjustment in
medical management.
Other controversies regarding the BP management in
dialysis patients include the effect of BP-lowering medi-
cations, such as RAAS inhibitors, β-blockers, and cal-
cium channel blockers, on the reduction of LVMI in
hypertensive patients [37, 38]. The Hypertension in
Hemodialysis Patients Treated with Atenolol or Lisinopril
(HDPAL) trial demonstrates the beneficial effect of β-
blocker to RAAS blockade in preventing cardiovascular
morbidity [26]. Our findings suggest that those on either a
β-blocker or RAAS blockade may have a protective role
but this needs to be confirmed by larger randomized con-
trolled trials with specifically targeted BP levels.
Contrary to past studies, we do not find that vascular
stiffness was significantly associated with LVMI [12]. Ar-
terial stiffness may be a factor associated with LV disease
over prolonged dialysis, as vascular calcification can
worsens and contribute to increased arterial stiffness
[12, 39]. Our study also includes incident and signifi-
cantly younger HD patients, whereas most studies in-
clude prevalent and older patients over age 65 years,
Table 2 Association of vascular, arterial, and volume measures with LVMI by linear regression among incident hemodialysis
participants
Variables n Univariable Multivariablea
β (95 % CI) P β (95 % CI) P
Vascular measurements
Blood pressure (per 10 mmHg)
Predialysis (3 month average) 383
Systolic 6.51 (3.69, 9.33) <0.001 7.26 (4.30, 10.23) <0.001
Diastolic 9.71 (5.52, 13.90) <0.001 10.05 (5.06, 15.04) <0.001
Predialysis (Prior to study visit) 380
Systolic 2.69 (0.83, 4.56) 0.005 2.46 (0.57, 4.35) 0.01
Diastolic 5.95 (2.92, 8.99) <0.001 3.93 (0.67, 7.20) 0.02
Non-dialysis (Seated) 387
Systolic 4.83 (2.94, 6.72) <0.001 5.00 (3.11, 6.89) <0.001
Diastolic 7.87 (4.68, 11.06) <0.001 7.28 (3.79, 10.77) <0.001
Non-dialysis (Supine) 367
Systolic 4.54 (2.62, 6.46) <0.001 4.72 (2.72, 6.72) <0.001
Diastolic 7.13 (3.91, 10.35) <0.001 6.25 (2.64, 9.85) 0.001
Mean arterial pressure (Non-dialysis) 370 0.57 (0.33, 0.82) <0.001 0.56 (0.29, 0.82) <0.001
Pulse pressure
Predialysis (3 months average) 383 0.35 (−0.02, 0.72) 0.07 0.71 (0.29, 1.13) 0.001
Predialysis (Prior to study visit) 380 0.12 (−0.13, 0.37) 0.34 0.26 (−0.01, 0.53) 0.05
Non-dialysis (Seated) 387 0.41 (0.13, 0.68) 0.003 0.65 (0.36, 0.94) <0.001
Non-dialysis (Supine) 367 0.38 (0.11, 0.65) 0.006 0.60 (0.30, 0.89) <0.001
Arterial stiffness measurements
Pulse wave velocity (m/s) 337 −0.42 (−1.78, 0.94) 0.55 0.19 (−1.41, 1.79) 0.82
Central augmentation index 365 −0.12 (−0.48, 0.25) 0.53 −0.03 (−0.41, 0.36) 0.88
Volume measurements
Tricuspid regurgitation (Non-dialysis) 211 0.32 (−0.29, 0.92) 0.30 0.10 (−0.51, 0.70) 0.76
Intradialytic weight gain (3 month average) 383 3.75 (−0.51, 8.01) 0.09 4.36 (−0.26, 8.98) 0.06
Intradialytic weight gain (Prior to study visit) 380 3.77 (1.17, 6.37) 0.005 3.25 (0.67, 5.83) 0.01
aAdjusted model included age, sex, ethnicity, body mass index, history of hypercholesterolemia, smoking, diabetes mellitus, coronary heart disease, congestive
heart failure, cause of end-stage renal disease, time since first nephrology visit, beta blocker use, RAAS blockade use, number of antihypertensive medication, and
dietary sodium intake
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which accounts for a higher burden of arterial stiffness
due to prolonged dialysis as well as the natural process
of aging. Studies with prevalent patients also introduce a
survivor bias, which needs to be considered when deter-
mining risk factors predicting cardiovascular disease.
Though we did not observe a direct association between
pulse wave velocity and LVMI, the association between
higher pulse pressure, which is determined by arterial
compliance and the intensity of wave reflections that are
influenced by arterial stiffness, and higher LVMI sug-
gests that reduced arterial compliance and distensibility
may still have an underlying role and potentially contrib-
ute to LVH [40].
Lastly, IDWG is associated with LVMI, however, the
association is attenuated after adjustment for other con-
founders. Another surrogate measure of volume status,
pulmonary pressure, is not significantly associated with
higher LVMI. In our study population of younger and di-
verse ethnicities, adjusting for dietary sodium intake
does not modify any associations. The results of our
study likely differ based on the change in residual kidney
function of dialysis patients over years. Most of our co-
hort is studied within the first 6 months from diagnosis.
This suggests that during the transition from reaching
ESRD to receiving dialysis, IDWG management may not
be a significant contributor until there is loss of residual
function.
A few limitations of this study include the cross-sectional
study design, which does not provide evidence of a
temporal relationship and would require a trial to demon-
strate normalization of blood pressure. Other measures of
volume status and pulmonary pressure and preload should
also be considered in future studies, as tricuspid regurgita-
tion by echocardiography alone may not be as accurate as
newer methods such as ultrasounds to detect lung conges-
tion [41], and TR velocity does not clearly reflect LV
preload in the presence of pulmonary vascular disease
even though few had documented disease. Nonetheless,
pulmonary hypertension is often observed together
with volume overload, and has been associated with
fluid volume status in past studies that showed a strong
association between left atrial diameter and chronic
volume overload [42]. Studies have also shown that
after a series of ultrafiltration sessions, thereby treating
volume overload, tricuspid regurgitation disappeared in
most patients [43]. Furthermore, it is difficult to accur-
ately measure volume status using one type of measure-
ment; therefore we used additional factors such as
IDWG, which is clinically relevant and available, to help
estimate volume status.
Despite the limitations, this well characterized cohort
of incident hemodialysis patients has been assessed in a
consistent manner on non-dialysis days with standard-
ized questions, adjudicated comorbidities and methods
for cardiovascular assessment, as well as extensive dia-
lysis unit BP and IDWG data. Moreover, our study co-
hort is predominantly African American (72.6 %), often
underrepresented in many studies or trials, despite
Table 3 Independent associations of non-dialysis seated blood pressure, arterial, and volume measures with LVMI by linear regression
among incident hemodialysis participants
Variables Model 1a Model 2b
(n = 177) (n = 177)
β (95 % CI) P β (95 % CI) P
Vascular measurements
Blood pressure (per 10 mmHg)
Non-dialysis seated systolic 5.64 (2.78, 8.49) <0.001 - -
Non-dialysis seated diastolic - - 7.29 (2.26, 12.31) 0.005
Arterial stiffness measurement
Pulse wave velocity (m/s) −0.05 (−2.44, 2.34) 0.97 0.41 (−2.01, 2.84) 0.74
Central augmentation index −0.36 (−0.88, 0.17) 0.19 −0.38 (−0.93, 0.16) 0.17
Volume measurement
Tricuspid regurgitation (Non-dialysis) −0.11 (−0.76, 0.54) 0.74 −0.04 (−0.70, 0.62) 0.90
Intradialytic weight gain (3-month average) 5.84 (−1.51, 13.19) 0.12 7.67 (0.06, 15.28) 0.05
Intradialytic weight gain (Prior to study visit) 2.03 (−1.91, 5.97) 0.31 1.69 (−2.33, 5.71) 0.41
aModel 1 included non-dialysis seated systolic blood pressure, pulse wave velocity, central augmentation index, tricuspid regurgitation, intradialytic weight gain
(3-month average), and intradialytic weight gain (prior to study visit), as well as baseline age, sex, ethnicity, body mass index, history of hypercholesterolemia,
smoking, diabetes mellitus, coronary heart disease, congestive heart failure, cause of end-stage renal disease, time since first nephrology visit, beta blocker use,
RAAS blockade use, number of antihypertensive medication, and dietary sodium intake
bModel 2 included non-dialysis seated diastolic blood pressure, pulse wave velocity, central augmentation index, tricuspid regurgitation, intradialytic weight gain
(3-month average), and intradialytic weight gain (prior to study visit), as well as baseline age, sex, ethnicity, body mass index, history of hypercholesterolemia,
smoking, diabetes mellitus, coronary heart disease, congestive heart failure, cause of end-stage renal disease, time since first nephrology visit, beta blocker use,
RAAS blockade use, number of antihypertensive medication, and dietary sodium intake
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comprising 10.4 % of the Medicare end stage renal dis-
ease population. Understanding cardiovascular risk in
this high risk population is important [44].
Conclusion
Among a younger and incident hemodialysis popula-
tion, afterload as measured by BP using either predialy-
sis or interdialytic measures, is most associated with
higher LVMI. This suggests that future studies should
consider the use of various BP measures in examining
the impact of BP on LVM and cardiovascular disease.
Findings from such studies could suggest that high BP
should be more aggressively treated to promote LVH
regression in incident hemodialysis patients.
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